Dr. Arthur Krieg is the founder and CSO of Checkmate Pharmaceuticals, with over 40 years of experience in the oligonucleotide field.
Dr. Krieg was CSO at Sarepta from January to July of 2014; co-founder and CEO at Translate Bio from 2011 to 2013; CSO of Pfizer’s Oligonucleotide Therapeutics Unit from 2008 to 2011; and co-founder, CSO of Coley Pharmaceutical Group from 1997 to 2008. Art co-founded the first antisense journal, Nucleic Acid Therapeutics, which he edited for 16 years, and the Oligonucleotide Therapeutics Society, for which he recently served as President. He has published more than 250 scientific papers and is an inventor on more than 50 issued US patents covering oligonucleotide technologies. Earlier in his career, he was a Staff Fellow at the NIH in the Arthritis Institute from 1986 to 1991 and then joined the University of Iowa, becoming Professor of Internal Medicine in the Division of Rheumatology. He has had 19 years of patient care experience.
Art completed undergraduate studies at Haverford College, received his M.D. from Washington University, and completed a residency in Internal Medicine at the University of Minnesota.